Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
biochemistry, genetics and molecular biology
Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
Molecular Cancer Therapeutics, Volume 3, No. 10, Year 2004
Notification
URL copied to clipboard!
Description
Purpose: The predictive value of topoisomerase-IIα (topo-II) has been evaluated in advanced breast cancer patients randomly treated with single-agent doxorubicin or docetaxel. Experimental design: Primary tumor samples from patients enrolled in a randomized, phase III clinical trial comparing single-agent doxorubicin (75 mg/m2 q3wks) with docetaxel (100 mg/m2 q3wks) were collected and topo-II status was evaluated by immunohistochemistry (clone KiS1). Results: Topo-II status was evaluated in 108 samples, 55 (51%) in the doxorubicin arm and 53 (49%) in the docetaxel arm. An increment of 10% in cells expressing topo-II is associated with a statistically significant odds ratio (OR; 95% confidence interval) of 1.09 (1.03 - 1.15; P = 0.002) for overall response to doxorubicin versus 1.002 (0.94-1.07; P = 0.95) in the docetaxel arm. With increasing topo-II, the favorable OR for overall response to docetaxel compared with doxorubicin decreases to become not significant in patients with topo-II tumor content > 10%. In a multivariate analysis, (a) HER-2 status seems positively correlated with overall response to chemotherapy (OR, 2.34; 95% confidence interval, 0.87-6.27; P = 0.09). (b) Overall response to doxorubicin is significantly lower than overall response to docetaxel (OR, 0.17; 95% confidence interval, 0.04-0.64; P = 0.009) but with a significant interaction term for doxorubicin-treated patients with topo-II tumor content > 10% (OR, 8.31; 95% confidence interval, 1.86-37.03; P = 0.05). Conclusions: (a) Topo-II overexpression confers a higher probability of response in the doxorubicin arm only. (b) Despite being a small retrospective study, this study is in line with previously reported studies and the hypotheses raised are now being tested in a prospective neoadjuvant trial. Copyright © 2004 American Association for Cancer Research.
Authors & Co-Authors
Durbecq, V.
Belgium, Brussels
Institut Jules Bordet
Paesmans, Marianne Msc
Belgium, Brussels
Institut Jules Bordet
Cardoso, Fatima
Belgium, Brussels
Institut Jules Bordet
Desmedt, Christine
Belgium, Brussels
Institut Jules Bordet
Di Leo, Angelo
Belgium, Brussels
Institut Jules Bordet
Chan, Stephen Y.T.
United Kingdom, Nottingham
Nottingham City Hospital
Friedrichs, Kay
Germany, Hamburg
Universitätsklinikum Hamburg-eppendorf
Pintér, Tamás
Hungary, Gyor
Petz Aladár Country Hospital
van Belle, Simon J.P.
Belgium, Ghent
Universitair Ziekenhuis Gent
Murray, Elizabeth M.
South Africa, Observatory
Groote Schuur Hospital
Bodrogi, István
Hungary, Budapest
Országos Onkológiai Intézet Budapest
Walpole, Euan T.
Australia, Woolloongabba
Princess Alexandra Hospital
Lesperance, B.
Canada, Montreal
Hôpital du Sacré-cœur-de-montréal
Korec, S.
Slovakia, Bratislava
Cancer Research Institute of Slovak Academy of Sciences
Crown, John P.A.
Ireland, Dublin
St Vincent's University Hospital
Simmonds, Peter D.
United Kingdom, Southampton
Southampton General Hospital
Perren J., Thimothy J.
United Kingdom, Leeds
St James's University Hospital
Leroy, J. Y.
Belgium, Brussels
Institut Jules Bordet
Rouas, Ghizlane
Belgium, Brussels
Institut Jules Bordet
Sotiriou, Christos
Belgium, Brussels
Institut Jules Bordet
Piccart-Gebhart, Martine J.
Belgium, Brussels
Institut Jules Bordet
Larsimont, Denis P.
Belgium, Brussels
Institut Jules Bordet
Statistics
Citations: 22
Authors: 22
Affiliations: 13
Identifiers
ISSN:
15357163
Research Areas
Cancer
Study Design
Cross Sectional Study
Cohort Study
Case-Control Study